# Whitening Efficacy Clinical Trial Report Template
# 미백 효능 임상시험 보고서 템플릿

---

## REPORT IDENTIFICATION

| Field | Value |
|-------|-------|
| **Report Title** | [Insert Title] |
| **Protocol Number** | [Insert Protocol Number] |
| **Sponsor** | [Company Name] |
| **Testing Institution** | [Institution Name] |
| **Principal Investigator** | [Name, MD/PhD] |
| **Report Date** | [YYYY-MM-DD] |
| **Report Version** | [Version Number] |

---

## 1. STUDY SUMMARY (연구 요약)

### 1.1 Study Objective (연구 목적)
To evaluate the whitening efficacy of [Product Name] in Korean women with facial hyperpigmentation.

### 1.2 Study Design (연구 설계)
- **Type**: [Randomized, Double-blind, Vehicle-controlled / Single-arm / etc.]
- **Duration**: [X] weeks
- **Sample Size**: [N] subjects per group

### 1.3 Test Article (시험제품)
- **Product Name**: [Name]
- **Batch Number**: [Batch #]
- **Key Ingredients**: [Active ingredients]
- **Concentration**: [%]

### 1.4 Key Results (주요 결과)
| Parameter | Baseline | Week [X] | Change | p-value |
|-----------|----------|----------|--------|---------|
| Melanin Index | [Value] | [Value] | [%] | [p] |
| L* value | [Value] | [Value] | [%] | [p] |
| ITA° | [Value] | [Value] | [%] | [p] |

### 1.5 Conclusion (결론)
[Product Name] demonstrated statistically significant [improvement/no effect] in skin whitening parameters after [X] weeks of use.

---

## 2. ETHICS AND REGULATORY (윤리 및 규제)

### 2.1 IRB Approval
- **IRB Name**: [Name]
- **Approval Number**: [Number]
- **Approval Date**: [Date]

### 2.2 Informed Consent
Written informed consent was obtained from all subjects prior to study enrollment.

### 2.3 Regulatory Compliance
This study was conducted in accordance with:
- Declaration of Helsinki
- Korean Good Clinical Practice (KGCP)
- MFDS Functional Cosmetics Guidelines

---

## 3. MATERIALS AND METHODS (재료 및 방법)

### 3.1 Test Materials (시험물질)

#### 3.1.1 Test Product
| Property | Description |
|----------|-------------|
| Product Name | [Name] |
| Formulation Type | [Essence/Serum/Cream/etc.] |
| Batch Number | [Number] |
| Manufacturing Date | [Date] |
| Expiration Date | [Date] |
| Active Ingredient(s) | [List with concentrations] |
| Storage Conditions | [Temperature, conditions] |

#### 3.1.2 Control Product (if applicable)
| Property | Description |
|----------|-------------|
| Product Name | [Vehicle control / Positive control] |
| Batch Number | [Number] |
| Composition | [Same as test without active / Established whitening product] |

### 3.2 Subject Selection (피험자 선정)

#### 3.2.1 Inclusion Criteria (선정기준)
- [ ] Korean women aged [X-Y] years
- [ ] Fitzpatrick skin type [III-IV]
- [ ] Visible facial hyperpigmentation (melasma, freckles, or sun spots)
- [ ] Willing to avoid excessive sun exposure during the study
- [ ] Able to provide written informed consent

#### 3.2.2 Exclusion Criteria (제외기준)
- [ ] Pregnancy or lactation
- [ ] History of skin cancer or precancerous lesions
- [ ] Active dermatological conditions (eczema, psoriasis, acne)
- [ ] Use of whitening products within 2 weeks prior to study
- [ ] Use of systemic retinoids within 6 months
- [ ] Laser treatment or chemical peel within 3 months
- [ ] Known allergy to any test product ingredients
- [ ] Participation in another clinical study within 1 month

### 3.3 Study Design (연구 설계)

#### 3.3.1 Treatment Schedule
| Week | Visit | Assessments |
|------|-------|-------------|
| 0 | Screening/Baseline | Eligibility, Consent, Baseline measurements |
| [2] | Follow-up 1 | Safety assessment |
| [4] | Follow-up 2 | Efficacy and safety assessments |
| [8] | Follow-up 3 | Efficacy and safety assessments |
| [12] | Final | Final efficacy and safety assessments |

#### 3.3.2 Application Instructions
- **Frequency**: Twice daily (morning and evening)
- **Amount**: Approximately [X] mL or [pea-sized amount]
- **Method**: Apply to cleansed face, gently massage until absorbed
- **Additional Care**: Use provided sunscreen (SPF [X]) during daytime

### 3.4 Efficacy Assessments (효능 평가)

#### 3.4.1 Melanin Index (Mexameter MX18)
- **Sites**: Both cheeks (malar area), forehead
- **Replicates**: 3 measurements per site
- **Environmental conditions**: [Temperature, Humidity]

#### 3.4.2 Colorimetry (L*a*b*)
- **Instrument**: [Chromameter CR-400 / Spectrophotometer]
- **Illuminant**: D65
- **Observer**: 10°
- **Sites**: Same as Mexameter

#### 3.4.3 Image Analysis
- **System**: [VISIA / equivalent]
- **Parameters**: UV spots, brown spots, evenness
- **Standardization**: [Cross-polarized, same positioning]

#### 3.4.4 Visual Assessment
- **Method**: MASI Score / Expert grading
- **Evaluator**: [Blinded dermatologist]

### 3.5 Safety Assessments (안전성 평가)

#### 3.5.1 Adverse Event Monitoring
- Spontaneous reporting at each visit
- Direct questioning about skin reactions
- Physical examination of application site

#### 3.5.2 Tolerability Assessment
| Parameter | Scale |
|-----------|-------|
| Erythema | 0-3 (none to severe) |
| Edema | 0-3 |
| Dryness | 0-3 |
| Stinging/Burning | 0-3 |

### 3.6 Statistical Analysis (통계 분석)

#### 3.6.1 Analysis Populations
- **ITT (Intent-to-Treat)**: All randomized subjects
- **PP (Per-Protocol)**: Subjects completing study without major deviations
- **Safety**: All subjects receiving at least one application

#### 3.6.2 Statistical Methods
- Descriptive statistics (mean, SD, median, range)
- Paired t-test or Wilcoxon signed-rank test (within-group)
- Independent t-test or Mann-Whitney U test (between-group)
- Repeated measures ANOVA (multiple time points)
- Significance level: α = 0.05

---

## 4. RESULTS (결과)

### 4.1 Subject Disposition (피험자 현황)

```
                    Screening
                        │
                    Enrolled (n=XX)
                        │
              ┌─────────┴─────────┐
              │                   │
        Test Group          Control Group
          (n=XX)               (n=XX)
              │                   │
        Completed (n=XX)   Completed (n=XX)
        Withdrawn (n=XX)   Withdrawn (n=XX)
```

**Withdrawal Reasons:**
| Reason | Test Group | Control Group |
|--------|------------|---------------|
| Lost to follow-up | [n] | [n] |
| Adverse event | [n] | [n] |
| Protocol violation | [n] | [n] |
| Withdrew consent | [n] | [n] |
| Other | [n] | [n] |

### 4.2 Demographics and Baseline Characteristics (인구통계학적 특성)

| Parameter | Test Group (n=XX) | Control Group (n=XX) | p-value |
|-----------|-------------------|----------------------|---------|
| Age (years) | XX.X ± X.X | XX.X ± X.X | [p] |
| Fitzpatrick Type III | XX (XX%) | XX (XX%) | [p] |
| Fitzpatrick Type IV | XX (XX%) | XX (XX%) | [p] |
| Baseline Melanin Index | XX.X ± X.X | XX.X ± X.X | [p] |
| Baseline L* | XX.X ± X.X | XX.X ± X.X | [p] |

### 4.3 Efficacy Results (효능 결과)

#### 4.3.1 Melanin Index

| Time Point | Test Group | Control Group | p-value (between) |
|------------|------------|---------------|-------------------|
| Baseline | XX.X ± X.X | XX.X ± X.X | NS |
| Week 4 | XX.X ± X.X | XX.X ± X.X | [p] |
| Week 8 | XX.X ± X.X | XX.X ± X.X | [p] |
| Week 12 | XX.X ± X.X | XX.X ± X.X | [p] |
| **Change from Baseline** | -X.X ± X.X | -X.X ± X.X | [p] |
| **% Change** | -X.X% | -X.X% | - |
| p-value (within) | [p] | [p] | - |

#### 4.3.2 L* Value (Skin Lightness)

| Time Point | Test Group | Control Group | p-value (between) |
|------------|------------|---------------|-------------------|
| Baseline | XX.X ± X.X | XX.X ± X.X | NS |
| Week 4 | XX.X ± X.X | XX.X ± X.X | [p] |
| Week 8 | XX.X ± X.X | XX.X ± X.X | [p] |
| Week 12 | XX.X ± X.X | XX.X ± X.X | [p] |
| **Change from Baseline** | +X.X ± X.X | +X.X ± X.X | [p] |
| **% Change** | +X.X% | +X.X% | - |
| p-value (within) | [p] | [p] | - |

#### 4.3.3 ITA° (Individual Typology Angle)

| Time Point | Test Group | Control Group | p-value (between) |
|------------|------------|---------------|-------------------|
| Baseline | XX.X ± X.X | XX.X ± X.X | NS |
| Week 12 | XX.X ± X.X | XX.X ± X.X | [p] |
| **Change from Baseline** | +X.X ± X.X | +X.X ± X.X | [p] |

#### 4.3.4 Visual Assessment (MASI Score)

| Time Point | Test Group | Control Group | p-value |
|------------|------------|---------------|---------|
| Baseline | XX.X ± X.X | XX.X ± X.X | NS |
| Week 12 | XX.X ± X.X | XX.X ± X.X | [p] |
| % Improvement | XX.X% | XX.X% | [p] |

### 4.4 Safety Results (안전성 결과)

#### 4.4.1 Adverse Events Summary

| Parameter | Test Group (n=XX) | Control Group (n=XX) |
|-----------|-------------------|----------------------|
| Subjects with any AE | XX (XX%) | XX (XX%) |
| Subjects with related AE | XX (XX%) | XX (XX%) |
| Subjects with serious AE | XX (XX%) | XX (XX%) |
| Discontinued due to AE | XX (XX%) | XX (XX%) |

#### 4.4.2 Adverse Events by Type

| Adverse Event | Test Group | Control Group |
|---------------|------------|---------------|
| Erythema | XX (XX%) | XX (XX%) |
| Itching | XX (XX%) | XX (XX%) |
| Dryness | XX (XX%) | XX (XX%) |
| Stinging/Burning | XX (XX%) | XX (XX%) |
| Acne | XX (XX%) | XX (XX%) |

#### 4.4.3 Tolerability Assessment

| Parameter | Baseline | Week 12 | p-value |
|-----------|----------|---------|---------|
| Erythema score | X.X ± X.X | X.X ± X.X | [p] |
| Dryness score | X.X ± X.X | X.X ± X.X | [p] |
| Overall tolerance | Excellent XX% / Good XX% / Fair XX% / Poor XX% |

---

## 5. DISCUSSION (고찰)

### 5.1 Efficacy Discussion
[Discuss the significance of findings, comparison with literature, mechanism of action]

### 5.2 Safety Discussion
[Discuss the safety profile, comparison with similar products]

### 5.3 Limitations
[Discuss study limitations - sample size, duration, population]

---

## 6. CONCLUSION (결론)

Based on the results of this [X]-week clinical trial with [N] subjects:

**Efficacy:**
- [Product Name] demonstrated statistically significant improvement in [parameters]
- Melanin Index decreased by [X]% (p < 0.05)
- L* value increased by [X]% (p < 0.05)
- [Additional findings]

**Safety:**
- [Product Name] was well-tolerated with no serious adverse events
- [X]% of subjects experienced mild, transient skin reactions

**Overall Conclusion:**
[Product Name] is effective for skin whitening/brightening and can support the claim "[Exact claim wording]" in accordance with MFDS functional cosmetics guidelines.

---

## 7. SIGNATURES (서명)

| Role | Name | Signature | Date |
|------|------|-----------|------|
| Principal Investigator | | | |
| Study Director | | | |
| Statistician | | | |
| Quality Assurance | | | |

---

## APPENDICES

- Appendix A: IRB Approval Letter
- Appendix B: Informed Consent Form
- Appendix C: Case Report Form
- Appendix D: Individual Subject Data
- Appendix E: Statistical Analysis Output
- Appendix F: Subject Photographs (Before/After)
- Appendix G: Certificates of Analysis (Test Products)
